Gilead Sciences of the US received CFDA approval for Sovaldi®, its once-daily oral treatment for chronic hepatitis C with ribavirin and/or interferon. Last year, Gilead began building a China commercial operation in Shanghai in preparation for the approval. The Shanghai office joins Gilead’s regulatory team in Beijing, a chemical manufacturing outsourcing group in Shanghai, and a new manufacturing facility under construction in Hangzhou, the company’s first plant outside the US. Gilead must still address the issue of Sovaldi’s price in China: in the US, a three-month treatment regimen costs close to $100,000.
Source: ChinaBio Today
